Amniotic Fluid Extracellular Vesicles for Consistent Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The variability in the molecular composition of amniotic tissue and fluid poses challenges for standardizing and reproducing the efficacy of amniotic-derived products in therapeutic applications, particularly in wound healing, due to donor-to-donor differences and uncertainties in recovery and storage processes.
Innovation Solution
The use of purified amniotic fluid-derived extracellular vesicles (EVs) as a standardized therapeutic agent, which are isolated and characterized for their potential in promoting wound healing by releasing growth factors and cytokines that stimulate tissue repair and promote skin and connective tissue homeostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole amniotic tissue and fluid are used for wound healing, then therapeutic effects are achieved, but variability in molecular composition reduces standardization and reproducibility
Solution Approach 1:
The patent extracts extracellular vesicles (EVs) from amniotic fluid through a multi-step purification process including differential centrifugation and filtration. This isolation of the active therapeutic component (EVs) from the variable amniotic fluid matrix eliminates donor-to-donor variability while preserving the wound healing benefits. The EVs are then standardized in terms of concentration, size, and purity for consistent therapeutic application.
Solution Approach 2:
The patent applies parameter changes by controlling physical and chemical conditions during EV isolation and characterization. Key parameters包括: particle size (50-200 nm diameter), buoyant density (1.10-1.21 g/ml in sucrose), and sedimentation characteristics (100,000×g). These standardized parameters ensure consistent EV quality and therapeutic efficacy across different batches and donors.
2Reliability
If amniotic fluid is processed to isolate EVs, then composition variability is reduced, but processing complexity increases
Solution Approach 1:
The purification process is segmented into distinct sequential steps: (1) differential centrifugation to remove cells and debris, (2) filtration through 0.22 µm and 0.1 µm filters to remove remaining particulates, and (3) density gradient centrifugation to isolate EVs based on buoyant density. This segmentation allows each step to be optimized independently and facilitates standardization of the overall process.
Solution Approach 2:
The patent uses sucrose density gradient as an intermediary medium to separate EVs from other amniotic fluid components. The sucrose gradient (1.10-1.21 g/ml) acts as a mediator that enables selective isolation of EVs based on their characteristic buoyant density, simplifying the purification process while achieving high composition consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Purified amniotic fluid-derived EVs provide a consistent and effective means to enhance wound healing by facilitating angiogenesis, re-epithelialization, and tissue regeneration, overcoming the variability issues associated with whole amniotic tissue and fluid compositions.
Implementation Method 1
purified amniotic fluid-derived extracellular vesicles (EVs)
Implementation Method 2
a buoyant density in sucrose of about 1.10-1.21 g/ml
Implementation Method 3
an average diameter of from about 50 nm to about 200 nm
Data Source
AI summary
The described invention provides compositions and methods for wound healing in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles from amniotic fluid and a pharmaceutically acceptable carrier.